Sanofi (ADR) (NYSE:SNY)
A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
aeprescott89
(< 20)
Submitted: 5/16/2013 4:33:10 PM :
Start Price:
$54.30
SNY Score:
-0.23
Aging population (especially in Europe) will continue to increase dependency on prescription medications, also doing some great things with R&D.
Recs
eksummers620
(48.92)
Submitted: 4/2/2013 12:06:15 AM :
Start Price:
$49.90
SNY Score:
+2.62
BRK holding
Recs
robotclo
(75.70)
Submitted: 3/19/2013 2:13:10 AM :
Start Price:
$47.83
SNY Score:
+6.45
Good year for health care...even in Europe
Recs
scrubs62074
(79.85)
Submitted: 2/8/2013 3:47:47 PM :
Start Price:
$45.22
SNY Score:
+10.51
High Volume Breakout on 02/08/13
Recs
bclan13
(99.31)
Submitted: 1/30/2013 1:50:57 AM :
Start Price:
$47.82
SNY Score:
-3.15
Lantus is going to get crushed by biosimilars. Would reevaluate if I saw some more interesting Growth moves
Recs
TerryHoodSr
(< 20)
Submitted: 1/11/2013 3:45:21 PM :
Start Price:
$47.51
SNY Score:
+1.22
EPS $6.90 TP $60
Recs
benyboy
(< 20)
Submitted: 12/9/2012 6:35:46 PM :
Start Price:
$44.83
SNY Score:
+4.18
Dodge & Cox International Stock Fund DODFX
Recs
flynthewest
(< 20)
Submitted: 11/16/2012 11:40:26 AM :
Start Price:
$41.04
SNY Score:
+9.63
Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that SNY's history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.
Recs
Fish08
(41.85)
Submitted: 9/7/2012 1:51:40 PM :
Start Price:
$41.03
SNY Score:
+17.01
Above average drug portfolio. Growth of existing and new products should more than make up for patent expirations.
Recs
kbelboe2
(35.64)
Submitted: 6/24/2012 12:27:05 PM :
Start Price:
$34.64
SNY Score:
+30.91
Buffett favorite of mine. Good current price. Cash generating cow.
Recs
cdb5556
(< 20)
Submitted: 5/20/2012 5:12:35 PM :
Start Price:
$33.52
SNY Score:
-34.32
no innovation, big patent cliff with Plavix/Lovenox/Lantus...nothing to replace them. Stock has done little over the past few years.
Recs
tad40
(99.76)
Submitted: 3/10/2012 3:38:27 PM :
Start Price:
$35.52
SNY Score:
+32.08
sells for 8% less than what Buffett paid.
Recs
Clint35
(62.06)
Submitted: 1/27/2012 6:27:56 PM :
Start Price:
$34.43
SNY Score:
+30.40
It's yielding 3.57% and 5 stars
Recs
ruinas
(< 20)
Submitted: 12/15/2011 5:29:13 PM :
Start Price:
$32.66
SNY Score:
+30.27
drug production and pipeline will boost earnings
Recs
willerbeats
(< 20)
Submitted: 9/13/2011 2:43:48 PM :
Start Price:
$30.05
SNY Score:
+39.39
India based biotech in under-represented market
Recs
GrizWin
(< 20)
Submitted: 9/6/2011 12:09:41 PM :
Start Price:
$32.07
SNY Score:
+25.90
Dividend makes is "safer" in the short run but with pipeline and genzyme long term also looks good
Recs
Keekers44
(85.09)
Submitted: 9/3/2011 12:09:41 PM :
Start Price:
$31.90
SNY Score:
+24.91
This stock is a Cramer favorite with a decent 3.8% yeild. Cramer believes this company has a low valuation, and is an accidental high yeilder. Ken Fisher of Fisher Asset Management recently increased holdings to over 14,750,000 shares.
Recs
GarlicEater7
(< 20)
Submitted: 8/10/2011 7:36:25 PM :
Start Price:
$28.90
SNY Score:
+41.22
Strong pipeline and nice dividend make SNY a compelling buy at this price.
Recs
mtrade1
(< 20)
Submitted: 6/15/2011 3:04:54 PM :
Start Price:
$33.94
SNY Score:
+29.12
want 2 get it on the down turn. down 4% strong co.
Recs
Laice1
(< 20)
Submitted: 6/3/2011 5:38:09 AM :
Start Price:
$35.39
SNY Score:
+25.74
A good defensive stock with a good divi.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 141 : 1 2 3 4 5 6 7 8 Next »